Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Processa Pharmaceuticals ( (PCSA) ) just unveiled an announcement.
On December 12, 2025, Processa Pharmaceuticals announced a 1-for-25 reverse stock split of its common stock, effective December 16, 2025. This move, which will see the stock trade under a new CUSIP number but retain its ‘PCSA’ symbol, is designed to consolidate shares and adjust securities without affecting overall ownership percentages, except for fractional shares.
The most recent analyst rating on (PCSA) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on Processa Pharmaceuticals stock, see the PCSA Stock Forecast page.
Spark’s Take on PCSA Stock
According to Spark, TipRanks’ AI Analyst, PCSA is a Underperform.
Processa Pharmaceuticals is facing significant financial challenges with no revenue generation and ongoing losses. Technical indicators point to bearish momentum, and valuation metrics highlight the high-risk nature typical of early-stage biotech firms. The company’s reliance on external financing for sustainability remains a concern.
To see Spark’s full report on PCSA stock, click here.
More about Processa Pharmaceuticals
Processa Pharmaceuticals operates in the pharmaceutical industry, focusing on developing and commercializing products to improve the survival and quality of life for patients who have unmet medical needs.
Average Trading Volume: 9,653,895
Technical Sentiment Signal: Strong Sell
Current Market Cap: $15.29M
Find detailed analytics on PCSA stock on TipRanks’ Stock Analysis page.